Avant Technologies Partner, Ainnova, Signs Pilot Program With Roche to Combat Diabetic Retinopathy
Rhea-AI Summary
Avant Technologies (OTCQB: AVAI) partner, Ainnova Tech, has announced a strategic alliance with Roche and Salud 360 to launch a pilot program combating diabetic retinopathy in Costa Rica. The program will utilize Ainnova's AI technology and non-mydriatic fundus cameras to analyze retinal images for early detection of the disease.
The initiative targets Costa Rica, where diabetes affects 10.4% of adults, with 20-40% of diabetic patients developing diabetic retinopathy. The program aims to prevent blindness through early detection, as 80% of diabetes-related blindness cases are preventable with timely intervention. If successful, Avant and Ainnova plan to expand the program to the United States, Canada, and Europe through their joint venture, Ai-nova Acquisition Corp (AAC).
Positive
- Strategic partnership with global biotech leader Roche enhances market credibility
- Potential expansion to major markets (US, Canada, Europe) if pilot successful
- Addresses large market opportunity with 10.4% diabetes prevalence in initial market
Negative
- to pilot program stage with no guaranteed success
- Initial implementation restricted to single market (Costa Rica)
- No immediate revenue impact disclosed
LAS VEGAS, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Avant Technologies Inc.’s (OTCQB: AVAI) (“Avant” or the “Company”), partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the company has entered into a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to begin a pilot program to combat diabetic retinopathy using Ainnova’s cutting-edge technology.
The pilot program will initially be implemented in Costa Rica where diabetes affects about
According to data from the Costa Rican Institute for Research and Teaching in Nutrition and Health (Inciensa), uncontrolled diabetes is the leading cause of preventable blindness in the country's adult population. To make matters worse, between
According to the World Health Organization,
Roche, Ainnova, and Salud 360 signed a strategic alliance to improve access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy using Ainnova’s advanced technology and a patient-centered approach.
The pilot program will use non-mydriatic fundus cameras and artificial intelligence - developed by Ainnova Tech - to automatically analyze retinal images and identify microscopic changes in the retina. Such changes would be an early indicator of diabetic retinopathy without the need for invasive tests.
“At Roche, we are committed to timely diagnosis of diseases to improve clinical outcomes and thus contribute to the sustainability of the healthcare system. By leveraging technology, we seek to improve lives, optimize diagnoses, and ensure that every patient has access to timely and effective treatment. With this model, we not only seek to address the problem of diabetic retinopathy, but also to establish a replicable path for other diseases that require innovative solutions,” said, Alvaro Soto, General Manager of Roche Central America, Caribbean, and Venezuela.
By implementing the pilot program in Costa Rica, this strategic alliance can take advantage of the country's robust healthcare system and its focus on technological innovation. Patients who are members of Salud 360 will be the first to benefit from screenings at affiliated clinics. Those at risk will be referred immediately to ophthalmology specialists, guaranteeing comprehensive and timely care.
The results of this pilot program will be the basis for developing the model beyond our borders to benefit communities facing similar challenges in accessing medical care.
Vinicio Vargas, Chief Executive Officer of Ainnova Tech and member of AAC’s Board of Directors, emphasized, “We are proud to be able to put our technology at the service of a project that has the potential to prove itself as a massive impact model in early detection, and which we believe is replicable globally. Today, we are starting with diabetic retinopathy, but the vision is that we can eventually multiply this same effort for other critical diseases that require innovative solutions.”
[2] https://www.who.int/es/news-room/fact-sheets/detail/blindness-and-visual-impairment
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas, founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
info@avanttechnologies.com
FAQ
What is the purpose of Avant Technologies (AVAI) partnership with Roche?
Where will Avant Technologies (AVAI) initially implement its diabetic retinopathy program?
What technology will Avant Technologies (AVAI) use in the diabetic retinopathy program?
What are the expansion plans for Avant Technologies (AVAI) diabetic retinopathy program?
